Year-end Sale % OFF 
Abstract
Monoclonal antibodies such as cetuximab and panitumumab, which target the epidermal growth factor receptor (EGFR), have single-agent activity in KRAS wild-type colorectal cancer. When these agents are added to chemotherapy in first- and second-line treatment of patients with metastatic colorectal cancer, response rates improve and progression-free survival is prolonged (JW Oncol Hematol May 19 2009 and JW Physician's First Watch Sep 28 2006). Skin …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
